Simulations Plus, Inc. (SLP) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Simulations Plus, Inc.'s filing signal continuing positive.

Simulations Plus, Inc. is a global leader in providing advanced software and consulting services to the biopharmaceutical sector, enhancing drug discovery, development, and commercialization. The company's model-informed drug development (MIDD) solutions leverage modeling and simulation to accelerate timelines, reduce R&D costs, and improve drug safety and efficacy. Its offerings span the entire drug development lifecycle, from early discovery through clinical operations to market launch, serving major pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies worldwide. The company operates with a remote-first philosophy and maintains headquarters in Research Triangle Park, NC, and an office in Paris, France.

Revenue is primarily driven by software license sales and consulting services provided to the biopharmaceutical and related industries. The software segment, which accounted for 58% of revenue in fiscal year 2025, includes products like ADMET Predictor and GastroPlus, while the services segment, accounting for 42% of revenue, offers expertise in pharmacokinetics, pharmacodynamics, and regulatory strategy.